Long-Term, Open Label Extension Study of Pemziviptadil (PB1046) in PAH Subjects Following Completion of Study PB1046-PT-CL-0004

PHASE2TerminatedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

April 10, 2019

Primary Completion Date

January 11, 2022

Study Completion Date

January 11, 2022

Conditions
Pulmonary Arterial Hypertension
Interventions
DRUG

Pemziviptadil (PB1046) Injection

Once-weekly subcutaneous injection

Trial Locations (16)

10016

NYU Langone Health, New York

14642

University of Rochester Medical Center, Rochester

15212

Allegheny General Hospital, Pittsburgh

15213

UPMC Presbyterian, Pittsburgh

30322

Emory University, The Emory Clinic, Atlanta

33125

University of Miami - Pulmonary Research Center, Miami

45219

The Lindner Center for Research and Education at The Christ Hospital, Cincinnati

45267

University of Cincinnati, Cincinnati

52242

University of Iowa Hospitals and Clinics, Iowa City

66160

University of Kansas Medical Center, Kansas City

73112

INTEGRIS Baptist Medical Center, Oklahoma City

75390

University of Texas Southwestern Medical Center, Dallas

92037

University of California San Diego, La Jolla

95817

University of California - Davis, Sacramento

02111

Tufts Medical Center, Boston

02115

Brigham and Women's Hospital, Boston

Sponsors
All Listed Sponsors
lead

PhaseBio Pharmaceuticals Inc.

INDUSTRY